Cleveland Clinic Laboratories

Hemostasis and Thrombosis Services

Trust in us for everything you need in a reference lab.
OUR MISSION

The Robert J. Tomsich Pathology and Laboratory Medicine Institute contributes to excellent patient care by providing comprehensive, high quality laboratory testing and patient-focused expert consultation. This mission is supported by innovative research and new test development, exceptional customer service, continuous quality improvement and leadership in education.

OUR VISION

We will provide the highest quality laboratory testing and expert pathology diagnosis to patients institutionally, regionally and nationally.

OUR VALUES

Clinical Excellence – We provide comprehensive and high quality laboratory testing in a patient-responsive manner.

Expert Diagnosis – Diagnoses are provided by subspecialty experts, and consultation with physicians is important for patient care.

Continuous Quality Improvement – We are continuously evaluating and implementing the best practices in laboratory testing across the testing spectrum.

Dedication to Our Staff – Our staff are our most valuable resource and are supported and recognized for their accomplishments.

Innovative Test Development – A continual focus on new test development is important to provide the best capabilities for patient diagnosis.

Research and Education – Research is crucial for leadership in laboratory medicine; education and development are important at all levels.

INTEGRITY
EXPERTISE
REPUTATION
FOCUS
INNOVATION

Trust in us for everything you need in a reference lab.
Hemostasis and Thrombosis Consultative Group

Cleveland Clinic Laboratories offers comprehensive testing for the evaluation of patients with inherited and acquired bleeding disorders, platelet dysfunction, thromboembolic complications, hypercoagulable states and anticoagulant monitoring.

We emphasize quality, a broad test menu, state-of-the-art testing, algorithm-based expert pathologist interpretation, customer service and competitive pricing.

Hemostasis disorders often are clinically puzzling, and laboratory testing in hemostasis is a rapidly changing field. Our staff of experienced pathologists can recommend appropriate laboratory testing for evaluation of patients with bleeding or thrombotic symptoms. We offer expert interpretation of laboratory results, integrating the patient’s medical and drug history, as well as recommendations for further evaluation of patients with hemostasis disorders.

Our extensive quality control assures safe, protected and expedited handling for each specimen to protect the quality of the results.

Cleveland Clinic Laboratories is accredited by the College of American Pathologists, certified by the CLIA and Medicare approved.
Specialized Diagnostic and Consultative Services

To evaluate patients with recurrent thrombosis, Cleveland Clinic Laboratories offers a well-defined array of testing for inherited and acquired abnormalities related to the hypercoagulable state. Our comprehensive testing and interpretative capabilities aid in diagnosing and planning appropriate intervention for these patients.

For patients with suspected congenital or acquired bleeding disorders, such as von Willebrand disease or hemophilia, we offer consultation by a pathologist with expertise in designing appropriate laboratory approaches for evaluation of coagulation, and fibrinolytic and platelet function for pinpointing these difficult-to-diagnose problems.

In addition to a complete range of diagnostic testing services, we also offer monitoring services for patients on anticoagulants, such as heparin, fondaparinux or warfarin. We offer testing to screen for resistance to antiplatelet drugs, such as aspirin or clopidogrel. Our staff are experienced in evaluating bleeding disorders in patients on anticoagulation therapy and in designing a diagnostic approach for evaluating the cause of heparin resistance. We offer pharmacogenetic testing to help clinicians select the appropriate dosing for warfarin and clopidogrel.

In consultation with the referring physician, our pathologists can develop a customized testing plan to meet the needs of the patient with a complex or unusual hemostasis disorder.
Core Laboratory Services

In addition to our traditional reference laboratory services, we offer complete core laboratory services for large, multicenter hemostasis research studies and clinical trials. Our experience in this area includes site coordination, protocol development, sample kit design and preparation, assay performance, database entry and data analysis.
Research

Research in the evaluation and development of state-of-the-art techniques and instrumentation to enhance the diagnosis of hemostasis disorders is constantly in progress.

Our research focuses on the development of new diagnostic laboratory tests for monitoring antiplatelet drugs, study of genetic risk factors for thrombosis and antiplatelet drug resistance, diagnostic assays for heparin-induced thrombocytopenia, and platelet flow cytometric techniques for diagnosing platelet dysfunction and activation. We are also involved in clinical trials of new antithrombotic agents, hemostatic evaluation of patients with artificial organs, and basic research to investigate the biocompatibility of biomaterials.

Continuing Education

Hemostasis and thrombosis lectures and educational programs are available for your professional and technical staff upon request.

For more information on continuing education programs or a complete list of lecture topics available through Cleveland Clinic Laboratories, please contact Client Services at 216.444.5755 or 800.628.6816.
For more information about Hemostasis and Thrombosis Services at Cleveland Clinic Laboratories, please contact:

**Customer Services:**
216.444.5755 | 800.628.6816 (toll-free)  
clientservices@ccf.org

**Submit specimens to:**
Cleveland Clinic Laboratories  
9500 Euclid Avenue, L15  
Cleveland, OH 44195

Complete information about tests, specimen preparation and ordering is available at clevelandcliniclabs.com
Every life deserves world class care.

9500 Euclid Avenue, Cleveland, OH 44195

Cleveland Clinic is an integrated healthcare delivery system with a main campus, 18 family health centers, eight community hospitals and locations in Ohio, Florida, Nevada, Toronto and Abu Dhabi. It is a not-for-profit group practice where nearly 3,000 staff physicians and scientists in 120 medical specialties collaborate to give every patient the best outcome and experience. Cleveland Clinic is ranked among America's top hospitals overall, and among the nation's leaders in every major medical specialty (U.S. News & World Report).

clevelandclinic.org

© The Cleveland Clinic Foundation 2014
How to Contact the Hemostasis and Thrombosis Consultative Group

For more information about Hemostasis and Thrombosis Services at Cleveland Clinic Laboratories, please contact:

**Scientific Information**
Kandice Kottke-Marchant, MD, PhD  
Chair, Robert J. Tomich Pathology and Laboratory Medicine Institute  
216.444.2484 | marchak@ccf.org  
Joyce Heesun Rogers, MD, PhD  
Medical Director, Hemostasis and Thrombosis  
216.445.2719 | rogersj5@ccf.org

**Technical Information**
Anne Beckman  
Manager, Hematopathology  
216.444.0483 | beckman2@ccf.org  
Laila Vengal, MT(ASCP)  
Lead Technologist, Hemostasis and Thrombosis  
216.445.1862 | vengall@ccf.org
## Hemostasis Testing Services

### Inherited Bleeding Disorders

- **Hemophilia A and B**
  - Diagnostic testing
  - Acquired coagulation inhibitors to factor VIII and IX
  - Testing for other acquired coagulation inhibitors available on request
- von Willebrand disease (including subtype analysis)
  - Diagnostic testing
  - DDAVP stimulation tests
  - Exon 28 sequencing

### Other bleeding disorders

- Factor deficiencies
- Hypofibrinogenemia
- Dysfibrinogenemia

### Acquired Bleeding Disorders

- Acquired factor inhibitors: detection and titer (Bethesda assay)
- Disseminated intravascular coagulation
- Vitamin K deficiency
- Super-warfarin poisoning
- Liver disease
- Acquired von Willebrand disease

### Platelet Dysfunction

- Acquired disorders
  - Drug effect
  - Myeloproliferative disorders

### Congenital disorders

- Glanzmann’s thrombasthenia
- Bernard-Soulier syndrome
- Platelet storage pool disorders

### Hypercoagulable State and Thromboembolic Disorders

- Defects and deficiencies of natural anticoagulants
  - Antithrombin
  - Protein C
  - Protein S
- Activated protein C resistance
  - Functional assays and molecular diagnosis of factor V Leiden gene mutation
- Multilevel testing for lupus anticoagulants and antiphospholipid antibodies
- Defects in thrombo-inflammatory markers
  - Factor VIII
  - C-reactive protein
  - Fibrinogen

### Hypofibrinogenemia / Dysfibrinogenemia

- Hypofibrinogenemia
- Hypofibrinolytic disorders

### Molecular testing for prothrombin G20210A mutation

- Hyperhomocysteinemia
  - Mutation analysis for methylene tetrahydrofolate reductase (MTHFR)

### Heparin-induced thrombocytopenia (HIT)

- Thrombotic thrombocytopenic purpura (TTP)
  - Congenital and acquired form
  - ADAMTS13 evaluation
Assays to Detect Bleeding Disorders

Coagulation Screening Assays
- Prothrombin Time (PT)/International Normalized Ratio (INR)
- Activated Partial Thromboplastin Time (APTT)
- Thrombin Time (TT)
- PT Mixing Studies
- APTT Incubated Mixing Study

von Willebrand Assays
- Factor VIII Activity
- von Willebrand Factor (VWF) Antigen
- Ristocetin Cofactor
- Collagen Binding Assay
- Ratio of Ristocetin Cofactor to VWF Antigen, Ratio of Collagen Binding Assay to VWF Antigen, and Ratio of Factor VIII Activity to VWF Antigen
- Platelet Function Screening by PFA-100™
- Ristocetin Induced Platelet Aggregation™
- von Willebrand Multimer Assay
- Exon 28 Sequencing
- von Willebrand Propeptide Antigen

Coagulation Factor Assays
- Fibrinogen Clottable (Clauss)
- Fibrinogen Antigen – Immunologic
- Reptilase
- Factor II Activity
- Factor V Activity
- Factor VII Activity
- Factor VIII Activity

- Factor IX Activity
- Factor X Activity
- Factor XI Activity
- Factor XII Activity
- Prekallikrein Activity
- Factor XIII (Clot solubility)

Factor XIII Quantitative

Inhibitor Studies
- Mixing Studies (PT and APTT Incubated)
- Bethesda Inhibitor Assay (Available to factor VIII, porcine factor VIII, factor IX, and other factors as needed)

Fibrinolytic Evaluation
- Fibrinogen Clottable (Clauss)
- Fibrinogen Antigen – Immunologic
- Plasminogen Activity – Chromogenic
- Plasminogen Antigen – Immunologic
- Alpha 2 Plasmin Inhibitor
- Fibrin/Fibrinogen Degradation Products
- D-dimer (Quantitative immunoassay)
- Euglobulin Lysis Time

Disseminated Intravascular Coagulation
- PT
- APTT
- Fibrinogen Clottable (Clauss)
- D-dimer (Quantitative immunoassay)
- Antithrombin Activity

*Available to local clients only

continued on back
Vitamin K Deficiency
- Factor II Activity
- Factor V Activity
- Factor VII Activity
- Factor IX Activity
- Factor X Activity

Hepatic Coagulopathy
- Fibrinogen Clottable (Clauss)
- Fibrinogen Antigen – Immunologic
- Reptilase Time
- Factor II Activity
- Factor V Activity
- Factor VII Activity
- Factor VIII Activity
- Factor IX Activity
- Factor X Activity
- Factor XI Activity
- Factor XII Activity
- D-dimer (Quantitative immunoassay)
Cleveland Clinic Laboratories

Assays to Detect Hypercoagulable Disorders

- Protein C Assay – Chromogenic
- Protein C Antigen
- Protein S – Clottable
- Protein S Immunologic (total & free)
- Factor VIII
- Fibrinogen
- C-Reactive Protein
- Activated Protein C Resistance
- Factor V Leiden Mutation by PCR
- Prothrombin G20210A Gene Mutation by PCR
- MTHFR Gene Mutation by PCR
- Anti-thrombin Assay – Chromogenic
- Anti-thrombin Antigen
- Homocysteine, plasma (HPLC)

Lupus Anticoagulant and Antiphospholipid Antibody Testing

- APTT Incubated Mixing Study
- Dilute Russell’s Viper Venom Time (DRVVT)
- Hexagonal Phase Phospholipid Neutralization Assay (STACLLOT)
- Platelet Neutralization Procedure (PNP)
- Anticardiolipin Antibody Assay (IgG, IgM, and IgA)
- Anti β2-GP1 Antibody Assay (IgG and IgM)

Heparin-Platelet Antibody Testing

- Heparin-Antiplatelet Factor 4 IgG ELISA
- Platelet Antibody/Heparin – by heparin induced platelet aggregation (HIPA)

Thrombotic Thrombocytopenic Purpura (TTP Testing)

- ADAMTS13 Activity
- ADAMTS13 Inhibitor
- ADAMTS13 Autoantibody
Cleveland Clinic Laboratories

Platelet Function Assays

- Platelet Count
- Platelet Morphology
- Platelet Aggregation (ADP, Epinephrine, Collagen, Arachidonic Acid, and Luminescent ATP dense granule release)*
- Ristocetin Induced Platelet Aggregation*
- Platelet Function Screening Test by PFA-100*
- Platelet Flow Cytometry** (Platelet surface analysis for fibrinogen receptor (GPIIb/IIIa), von Willebrand factor receptor (GPIb/IX), and Collagen receptor (GPIa/IIa), Assessment of platelet granules and platelet release (Mepacrine uptake/release and P-selectin (CD62) expression)
- Platelet Electron Microscopy (for ultra structural morphology and assessment of storage pool disorder)

Anticoagulation and Antiplatelet Monitoring
- Heparin Assay (by Factor Xa inhibition method)
- Low Molecular Weight Heparin Assay (by Factor Xa inhibition method)
- Aspirin and Clopidogrel Resistance by Platelet Aggregation*
- Warfarin Level (HPLC)
- Brodifacoum Level (for superwarfarin detection)
- Genetic Tests of Cytochrome P450 2C19 (CYP 2C19) for Clopidogrel and Other Drug Metabolism
- Genetic Tests of Cytochrome P450 2C9 (CYP 2C9) and Vitamin K Epoxide Reductase Subunit 1 (VKORC1) for Warfarin Therapy
- Fondaparinux Assay (by Factor Xa inhibition method)
- Dabigatran Assay (by chromogenic anti-IIa assay)
- Rivaroxaban assay (by chromogenic anti-Xa assay)

Other Testing Available
- Viscosity, serum
- Viscosity, whole blood
- Thromboelastometry*

* Available to local clients only

** Platelet flow cytometry: Platelet surface analysis available for remote clients; Assessment of platelet granules and release available to local clients only
Panels for the Evaluation of Complex Hemostasis Problems

These panels are available to evaluate patients with complex hemostasis problems. Components of these panels may be ordered separately, if not all tests are necessary given a patient's condition.

**Lupus Anticoagulant Panel**
- PT
- APTT
- Thrombin time
- Incubated APTT mixing study
- Dilute Russell's viper venom time (DRVVT)
- Hexagonal phase phospholipid neutralization (STA/CLOT)
- Platelet neutralization procedure (PNP)
- Anticardiolipin antibodies (IgG, IgM, and IgA)
- Anti 82 GP1 antibody assay (IgG and IgM)

**Hypercoagulation Panel**
- PT
- APTT
- Hexagonal phase phospholipid neutralization (STA/CLOT)
- Anticardiolipin antibodies (IgG, IgM, and IgA)
- Fibrinogen, Factor VIII activity, C-reactive protein
- Antithrombin activity
- Protein C activity
- Protein S clottable
- Activated Protein C (APC)-resistance
- Plasma homocysteine
- Prothrombin G20210A mutation

**von Willebrand Panel**
- PT
- APTT
- Platelet function screen
- Factor VIII activity
- von Willebrand factor antigen
- Ristocetin cofactor and Collagen binding assay with their ratios
- Ristocetin induced platelet aggregation
- von Willebrand factor multimer analysis

*Exon 28 sequencing is performed if needed.*

The following tests may be added on: Incubated APTT mixing study, DRVVT, PNP, 82 GP1 antibody, Protein S Antigen, Protein C antigen and Factor V Leiden mutation performed, if needed.

*Available to local clients only*
Cleveland Clinic Laboratories

Hemostasis and Thrombosis Staff

Kandice Kottke-Marchant, MD, PhD
Chair, Robert J. Tomsich Pathology & Laboratory Medicine Institute,
Laboratory Medicine
Board Certifications:
Hematology, Anatomic Pathology, Clinical Pathology
Specialty Interests:
Hemostasis and Thrombosis, Hematopathology
Phone: 216.444.2484
Email: marchak@ccf.org

Sarah Ondrejka, DO
Laboratory Medicine, Section of Hematopathology
Board Certifications:
Hematology, Anatomic Pathology, Clinical Pathology
Specialty Interests:
Hematopathology, Hemostasis and Thrombosis
Phone: 216.445.1662
Email: ondrejs@ccf.org

Suzanne Bakdash, MD
Laboratory Medicine, Section of Transfusion Medicine
Board Certifications:
Blood Banking/Transfusion Medicine, Anatomic Pathology, Clinical Pathology
Specialty Interests:
Transfusion medicine, Hemostasis and Thrombosis
Phone: 216.444.4616
Email: bakdass@ccf.org

Joyce Heesun Rogers, MD, PhD
Laboratory Medicine, Section of Hematopathology, Medical Director, Hemostasis and Thrombosis
Board Certifications:
Hematology, Anatomic Pathology, Clinical Pathology
Specialty Interests:
Hematopathology, Hemostasis and Thrombosis, Hematopathology, Cytogenetics
Phone: 216.445.2719
Email: rogersj5@ccf.org

Megan Nakashima, MD
Laboratory Medicine, Section of Hematopathology, Medical Director, Automated Hematology
Board Certifications:
Hematology, Anatomic Pathology, Clinical Pathology
Specialty Interests:
Hematopathology, Hemostasis and Thrombosis
Phone: 216.442.5636
Email: nakashm@ccf.org

Karl Theil, MD
Laboratory Medicine, Director of the Pathology Residency Program, Section of Hematopathology
Board Certifications:
Hematology, Anatomic Pathology, Clinical Pathology
Specialty Interests:
Hematopathology, Hemostasis and Thrombosis, Bone Marrow Transplantation, Cytogenetics
Phone: 216.444.1086
Email: theilk@ccf.org
Adequate specimen collection, appropriate specimen handling, processing and storage are necessary for accurate coagulation testing.

**Specimen Collection**
For most coagulation tests and factor assays, use the following instructions. For individual requirements, refer to specific tests.

Obtain venous blood by drawing a clearing tube prior to obtaining the specimen. Draw the specimen in a light blue top sodium citrate tube using 3.2% buffered sodium citrate with a 19- to 21-gauge needle. Avoid stasis and contamination of the specimen by tissue thromboplastin.

Mix blood with anticoagulant (3.2% buffered sodium citrate) by gentle inversion. An exact ratio of 9 parts blood to 1 part anticoagulant should be maintained and the collection tube must be filled to at least 90% fill volume.

Note: If the hematocrit of the sample is ≥ 55%, the anticoagulant ratio will not be maintained and spuriously elevated PT and APTT values will be seen. Contact the laboratory for instructions on how to draw these patients.

**Specimen Handling, Processing and Storage for Whole Blood Specimens**
The whole blood specimen should be stored at room temperature and transported to the laboratory within 1 hour. The acceptable time between collection and processing depends on the coagulation test requested. Platelet functional studies need to be completed within 3-4 hours from the time of phlebotomy.

<table>
<thead>
<tr>
<th>Test</th>
<th>Time and Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT</td>
<td>Test within 24 hours</td>
</tr>
<tr>
<td></td>
<td>Storage at 18-24°C</td>
</tr>
<tr>
<td>APTT (nonheparin)</td>
<td>Test within 4 hours</td>
</tr>
<tr>
<td></td>
<td>Storage at 18-24°C</td>
</tr>
<tr>
<td>APTT (heparin)</td>
<td>Test within 1 hour</td>
</tr>
<tr>
<td></td>
<td>Storage at 18-24°C</td>
</tr>
<tr>
<td>Other Coagulation tests*</td>
<td>Test within 4 hours</td>
</tr>
<tr>
<td></td>
<td>Storage at 18-24°C</td>
</tr>
</tbody>
</table>

*e.g. thrombin time, protein C, factor V, factor VIII

continued on back
The specimen should be visually inspected for an appropriate specimen collection, excess hemolysis, icterus or lipemia. Grossly hemolyzed specimens should not be used for coagulation testing.

**Specimen Handling for centrifuged specimens (>4 hour transport time)**

If the specimen cannot be transported to the laboratory within 4 hours, please process according to the following procedure. The specimen should be centrifuged at 1,500 x g for no less than 15 minutes to result in platelet poor plasma with a platelet count of <10,000/ul. Immediately remove 2 ml (min: 1 ml) platelet-poor plasma from the red cells using a plastic pipette. Place the plasma into a properly labeled plastic vial. Glass vials will not be accepted. The specimen should be frozen immediately at -70°C or below. Each assay requested must be submitted in a labeled, separate plastic vial. The specimen should be frozen during transport on dry ice.

**Technical Consideration**

In order to produce valid results for coagulation tests and factor assays, specimen integrity is crucial and must be maintained. Specimens should be frozen within 4 hours of phlebotomy. Short draw samples (Vacutainer less than 2/3 full) are not acceptable.

Some assays may be performed on a priority basis if a medical emergency exists. Contact Customer Service to make arrangements.

All requests for coagulation assays should include a brief patient history and other pertinent clinical information (i.e., medications, blood products, etc.). The Hemostasis and Thrombosis Patient Information form must be filled out and submitted with the specimen.